Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
- Joseph Domachowske; Yue Chang; Victoria Atanasova; Fernando Cabañas; Kenji Furuno; Kim Nguyen
Access Resources
About
This study looks at the safety of giving a second dose of nirsevimab to children with heart or lung disease before their second RSV season. It describes how nirsevimab, a long-lasting antibody, is similar in safety to palivizumab and effective in preventing severe RSV infections. The research involved 262 children and found no serious side effects or deaths. Most kids reached the desired levels of protection against RSV. The study was done during COVID-19, which affected RSV spread but still showed that nirsevimab is safe for these high-risk children entering their second season.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.